Prevalence of hiv-1 drug resistance in treated patients with viral load >50 copies/ml in 2009: A french nationwide study

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 6, 2013, Pages 1400-1405

  Assoumou, Lambert ^a,b   Descamps, Diane ^c   Yerly, Sabine ^d   Santos, Georges Dos ^e   Marcelin, Anne Geneviève ^a,b,f   Delaugerre, Constance ^c   Morand Joubert, Laurence ^a,b,g   Ruffault, Annick ^h   Izopet, Jacques ⁱ   Plantier, Jean Christophe ^h   Pakianather, Sophie ^a,b   Montes, Brigitte ^j   Chaix, Marie Laure ^k   Wirden, Marc ^a,b,f   Costagliola, Dominique ^a,b,f   Masquelier, Bernard ^l  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e CENTRE HOSPITALIER UNIVERSITAIRE DE FORT DE FRANCE   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g HÔPITAL SAINT ANTOINE   (France)

^h RENNES UNIVERSITY HOSPITAL   (France)

ⁱ TOULOUSE UNIVERSITY HOSPITAL   (France)

^j MONTPELLIER UNIVERSITY HOSPITAL   (France)

^k UNIVERSITÉ PARIS DESCARTES   (France)

^l BORDEAUX UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Antiretroviral therapy; Epidemiology; HIV 1 drug resistance; Multidrug resistance; Plasma HIV RNA; Virological failure

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR PLUS RITONAVIR; INDINAVIR; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; PROTEINASE; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR PLUS SAQUINAVIR; RITONAVIR PLUS TIPRANAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ALGORITHM; ARTICLE; FEMALE; FRANCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MALE; THERAPY RESISTANCE; TREATMENT FAILURE; VIRUS LOAD;

ANTIRETROVIRAL THERAPY; EPIDEMIOLOGY; HIV-1 DRUG RESISTANCE; MULTIDRUG RESISTANCE; PLASMA HIV RNA; VIROLOGICAL FAILURE;

AGED; AMINO ACID SEQUENCE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DATA COLLECTION; DRUG RESISTANCE, VIRAL; FEMALE; FRANCE; GENOTYPE; HEALTH SURVEYS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD;

EID: 84885117114     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt033     Document Type: Article

References (17)

1. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-60.
2. Hammer SM, Saag MS, Schechter M et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society- USA panel. JAMA 2006; 296: 827-43.
3. Hirsch MS, Brun-Vezinet F, Clotet B et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003; 37: 113-28.
4. Costagliola D, Descamps D, Assoumou L et al. Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study. J Acquir Immune Defic Syndr 2007; 46: 12-8.
5. Descamps D, Delaugerre C, Masquelier B et al. Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance. J Med Virol 2006; 78: 153-60.
6. Whitcomb JM, Parkin NT, Chappey C et al. Broad nucleoside reversetranscriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis 2003; 188: 992-1000.
7. Xu HT, Oliveira M, Quan Y et al. Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function. J Antimicrob Chemother 2010; 65: 2291-9.
8. Di Giambenedetto S, Bracciale L, Colafigli M et al. Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study. Antivir Ther 2007; 12: 835-9.
9. Bannister WP, Cozzi-Lepri A, Kjaer J et al. Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy. J Antimicrob Chemother 2011; 66: 901-11.
10. Cohen CJ, Andrade-Villanueva J, Clotet B et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011; 378: 229-37.
11. Descamps D, Chaix ML, Montes B et al. Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France. J Antimicrob Chemother 2010; 65: 2620-7.
12. Wittkop L, Breilh D, Da Silva D et al. Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort. J Antimicrob Chemother 2009; 63: 1251-5.
13. Asboe D, Aitken C, Boffito M et al. British HIVAssociation guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011. HIV Med 2012; 13: 1-44.
14. EACS. European AIDS Clinical Society guidelines. http://www. europeanaidsclinicalsociety.org (30 August 2012, date last accessed).
15. Prise en charge médicale des personnes infectées par le VIH. http:// www.sante.gouv.fr/IMG/pdf/Rapport_2010_sur_la_prise_en_charge_medicale_ des_personnes_infectees_par_le_VIH_sous_la_direction_du_Pr-_Patrick_Yeni . pdf (30 August 2012, date last accessed).
16. Sterrantino G, Zaccarelli M, Colao G et al. Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis. Infection 2012; 40: 311-8.
17. Castagliola D, Ledergerber B, Torti C et al. Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Lancet Infect Dis 2012; 12: 119-27.